prep upcom earn day
updat model recent event ahead earn
lower ep
driven predominantli higher share count due
septemb public offer chang upfront/mileston
payment assumpt target price base dcf analysi remain
dilut higher share count larg off-set
rais inclus mileston payment servier
initi roccella phase studi
multipl upcom event octob result releas
oct expect sale vs consensu ep
vs consensu said investor highli
focus earn clinical-stag compani investor focu remain
pipelin includ full finch data filgotinib rheumatoid
arthriti ra present acr oct detail review
pipelin day oct initi data falcon
studi cystic fibrosi late oct/earli
maintain neutral rate glpg lead asset filgotinib remain key driver
stock finch look competit wait full data acr
continu believ time-to-market may biggest challeng
product commerci given xeljanz gain traction ra
approv ulcer coliti lly/inci olumi
market upadacitinib like next year xeljanz
expect go gener end time gild/glpg
success commerci filgotinib somewhat limit assum
launch peak probabl adjust sale base
po drive close half total valuat compani risk
call includ acceler delay approv filgotinib well
either better- worse-than-expect data pipelin
valuat metric
number share
price month
amsterdam exchang
close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
galapago clinic stage biotech compani focus
develop novel treatment rheumatoid arthriti inflammatori
bowel diseas cystic fibrosi idiopath pulmonari fibrosi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base po filgotinib
increas peak probabl adjust end user sale
cf franchis blue sky valuat base dcf
driven wacc discount cash flow
termin growth rate thereaft
grey sky valuat base po filgotinib
po cf franchis grey sky valuat base
dcf driven wacc discount cash flow
termin growth rate thereaft
amsterdam exchang close
charl martineau pm univers toronto figur glpg incom statement
sale
net profit/ loss continu oper
gross margin ex-royalti incom
compani mention price
